Zydus receives EIR for oncology injectable manufacturing facility in Ahmedabad SEZ1
The facility has been classified as Voluntary Action Indicated
The facility has been classified as Voluntary Action Indicated
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
Importantly, the combination of giredestrant and everolimus was well tolerated
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The inspection concluded with zero form 483 observations
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Subscribe To Our Newsletter & Stay Updated